TIDMNSCI

RNS Number : 0830J

NetScientific PLC

26 June 2017

NetScientific plc

("NetScientific" or the "Company" or the "Group")

Glycotest Update

London, UK - June 26(th) 2017 - NetScientific plc ("NetScientific", AIM:NSCI), the transatlantic IP commercialisation group focused on healthcare, provides an update on the series A fundraising being undertaken by its portfolio company Glycotest, a US-based diagnostics company, as outlined in the Circular issued to shareholders following the Company's placing and subscription of new shares on 26 May 2017 (the "Circular").

The Company continues to anticipate closing the Series A round within the second half of 2017, but does not now expect to sign the relevant documentation by the end of June 2017, as was previously stated as the Company's aim in the Circular.

As at 31 December 2016 the NetScientific had invested GBP2.4 million in Glycotest. The Company expects that the delay will lead to an increase in its GBP0.5m expected spend in Glycotest in 2017, as stated in the Circular, but with overall spend remaining under GBP1.0m in 2017.

# # #

For more information, please contact:

 
  NetScientific                            Tel: +44 (0)20 3514 1800 
   François R. Martelet, 
   M.D., CEO 
   Ian Postlethwaite, 
   CFO 
  Consilium Strategic 
   Communications                          Tel: +44 (0)20 3709 5700 
   Mary-Jane Elliott /            netscientific@consilium-comms.com 
   Jessica Hodgson / 
   Chris Welsh / Laura 
   Thornton 
  Stifel Nicolaus Europe                  Tel: +44 (0) 20 7710 7600 
   Limited (NOMAD and Broker) 
   Jonathan Senior / David 
   Arch / Ben Maddison

About NetScientific

NetScientific is an IP commercialisation group focused on healthcare with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases. For more information, please visit the website at www.netscientific.net

About Glycotest

Glycotest is a US based diagnostics company, developing biomarkers for clinical laboratory

services used in the diagnosis of liver cancers and fibrosis-cirrhosis, which the Directors

believe represents a $1 billion market opportunity. Its blood-based biomarkers take advantage

of sugar-related disease signals and the company has issued patents to over 50 serum proteins

with sugar structures that are altered in liver disease. The biomarkers are being developed into

tests and test panels intended for the surveillance of patients with serious liver disease.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCSEDEEIFWSEDM

(END) Dow Jones Newswires

June 26, 2017 02:00 ET (06:00 GMT)

Netscientific (LSE:NSCI)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Netscientific Charts.
Netscientific (LSE:NSCI)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Netscientific Charts.